Journal: Bioactive Materials

Article Title: Leukocyte/platelet hybrid membrane-camouflaged dendritic large pore mesoporous silica nanoparticles co-loaded with photo/chemotherapeutic agents for triple negative breast cancer combination treatment

doi: 10.1016/j.bioactmat.2021.04.004

Figure Lengend Snippet: Schematic illustrations for preparation method of LPHM@DDI NPs (A) and their synergistic effects in TNBC treatment via combining PTT/PDT with chemotherapy (B).

Article Snippet: Mouse TNBC cell line 4T1 and mouse macrophage cell line Raw 264.7 were sourced from BioVector NTCC (Beijing, China).

Techniques:

Journal: Bioactive Materials

Article Title: Leukocyte/platelet hybrid membrane-camouflaged dendritic large pore mesoporous silica nanoparticles co-loaded with photo/chemotherapeutic agents for triple negative breast cancer combination treatment

doi: 10.1016/j.bioactmat.2021.04.004

Figure Lengend Snippet: In vitro PTT/PDT performances and drug releases of LPHM@DDI NPs. IR thermal images of DLMSNs, DOX, IR780, DDI NPs, and LPHM@DDI NPs (A) and their temperature changes (B) within the 10-min laser irradiation period. (C) Fluorescence intensities of SOSG in the dispersions of DLMSNs, DOX, IR780, DDI NPs, and LPHM@DDI NPs after 2, 4, 6, 8, and 10 min of laser irradiation. (D) Fluorescence intensities of DCFH-DA in 4T1 cells after incubation of IR780, DOX, DDI NPs, and LPHM@DDI NPs alone (‒L) and followed by laser irradiation (+L). ** represents P < 0.01 vs. control; ## represents P < 0.01 between two groups. (E) In vitro release profiles of DOX from LPHM@DDI NPs alone and (F) their pre-procession with 10-min laser irradiation at different pH values.

Article Snippet: Mouse TNBC cell line 4T1 and mouse macrophage cell line Raw 264.7 were sourced from BioVector NTCC (Beijing, China).

Techniques: In Vitro, Irradiation, Fluorescence, Incubation, Control

Journal: Bioactive Materials

Article Title: Leukocyte/platelet hybrid membrane-camouflaged dendritic large pore mesoporous silica nanoparticles co-loaded with photo/chemotherapeutic agents for triple negative breast cancer combination treatment

doi: 10.1016/j.bioactmat.2021.04.004

Figure Lengend Snippet: Cellular uptake and intracellular localization of LPHM@DDI NPs. (A) Confocal microscopic images of 4T1 cells after 2 h of incubation with DDI, LM@DDI, PM@DDI, and LPHM@DDI NPs. Mean fluorescence intensities (MFIs) of DOX (B) and IR780 (C) in 4T1 cells after incubation with the above NPs. Flow cytometry analysis of Raw 264.7 cells after 1 h of incubation of DDI, LM@DDI, PM@DDI and LPHM@DDI NPs (D) and MFIs of intracellular DOX (E). ** represents P < 0.01 vs. control.

Article Snippet: Mouse TNBC cell line 4T1 and mouse macrophage cell line Raw 264.7 were sourced from BioVector NTCC (Beijing, China).

Techniques: Incubation, Fluorescence, Flow Cytometry, Control

Journal: Bioactive Materials

Article Title: Leukocyte/platelet hybrid membrane-camouflaged dendritic large pore mesoporous silica nanoparticles co-loaded with photo/chemotherapeutic agents for triple negative breast cancer combination treatment

doi: 10.1016/j.bioactmat.2021.04.004

Figure Lengend Snippet: In vitro synergistic anti-TNBC effects of LHPM@DDI NP-mediated combination treatment. Cytotoxicities of DOX with and without laser irradiation (A), IR780 with and without laser irradiation (B), and DDI NPs with and without laser irradiation (C) in 4T1 cells at different drug concentrations. (D) Cytotoxicities of DDI, LM@DDI, PM@DDI, and LPHM@DDI NPs with and without laser irradiation at the DOX and IR780 concentrations of 0.75 and 1.0 μg/mL, respectively. * and ** represent P < 0.05 and P < 0.01 between two groups. (E) Fluorescence microscopic images of 4T1 cells treated with LPHM@DDI NPs alone and followed by laser irradiation after co-staining of calcein-AM and ethidium homodimer-1. Green and red fluorescence indicate liver and dead cells. (F) Flow cytometry analysis of apoptosis in 4T1 cells treated with DDI, LM@DDI, PM@DDI, and LPHM@DDI NPs alone and followed by laser irradiation. The DOX and IR780 concentrations were 0.45 and 0.6 μg/mL, respectively. Four quadrants (Q1, Q2, Q3 and Q4) represent dead cells, late apoptotic cells, early apoptotic cells and live cells, respectively.

Article Snippet: Mouse TNBC cell line 4T1 and mouse macrophage cell line Raw 264.7 were sourced from BioVector NTCC (Beijing, China).

Techniques: In Vitro, Irradiation, Fluorescence, Staining, Flow Cytometry

Journal: Bioactive Materials

Article Title: Leukocyte/platelet hybrid membrane-camouflaged dendritic large pore mesoporous silica nanoparticles co-loaded with photo/chemotherapeutic agents for triple negative breast cancer combination treatment

doi: 10.1016/j.bioactmat.2021.04.004

Figure Lengend Snippet: Biodistribution and tumor accumulation of LPHM@DDI NPs in TNBC mice. (A) In vivo fluorescence images of 4T1 tumor-bearing mice at 6, 12, 24 and 48 h post-administration of PBS (the control), DDI NPs, LM@DDI NPs, PM@DDI NPs, and LPHM@DDI NPs. The dotted-red circle represents the tumor location in the control mouse. Ex vivo fluorescence images (B) and mean radiant efficiencies (MREs) (C) of the major organs and tumors isolated from the above mice. H, Li, S, Lu, K and T indicate the heart, liver, spleen, lung, kidney and tumor, respectively. * and ** represent P < 0.05 and P < 0.01 between two groups.

Article Snippet: Mouse TNBC cell line 4T1 and mouse macrophage cell line Raw 264.7 were sourced from BioVector NTCC (Beijing, China).

Techniques: In Vivo, Fluorescence, Control, Ex Vivo, Isolation

Journal: Bioactive Materials

Article Title: Leukocyte/platelet hybrid membrane-camouflaged dendritic large pore mesoporous silica nanoparticles co-loaded with photo/chemotherapeutic agents for triple negative breast cancer combination treatment

doi: 10.1016/j.bioactmat.2021.04.004

Figure Lengend Snippet: In vivo synergistic anti-TNBC effects of LPHM@DDI NP-mediated combination treatment. Tumor growth curves of 4T1 tumor-bearing mice treated with PBS (the control), the DOX/IR780 mixture, DDI NPs, LM@DDI NPs, PM@DDI, and LPHM@DDI NPs alone (A) and followed by laser irradiation (B). Photos of representative tumors sourced from the mice with various treatments (C) and microscopic images of their sections with H&E staining (D). (E) Photos of representative mice at 0, 5 and 18 d during the treatment period. Weight change curves of the mice receiving the above-mentioned treatments (F) and followed by laser irradiation (G). Microscopic images of tumor sections with TUNEL staining (H) and CD31 immunohistochemical staining (I) from the mice at 2 d during treatment period. The red arrows represent apoptotic cells or CD31-stained areas in tumor sections. (J) Comparison of MVDs calculated from CD31-stained tumor sections in various treatment groups. ** represents P < 0.01 vs. control; ## represents P < 0.01 between two groups.

Article Snippet: Mouse TNBC cell line 4T1 and mouse macrophage cell line Raw 264.7 were sourced from BioVector NTCC (Beijing, China).

Techniques: In Vivo, Control, Irradiation, Staining, TUNEL Assay, Immunohistochemical staining, Comparison